BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36385665)

  • 1. Chloroquine induces transitory attenuation of proliferation of human lung cancer cells through regulation of mutant P53 and YAP.
    Saini H; Choudhary M; Sharma H; Chowdhury S; Mukherjee S; Chowdhury R
    Mol Biol Rep; 2023 Feb; 50(2):1045-1058. PubMed ID: 36385665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth inhibitory role of the p53 activator SCH 529074 in non‑small cell lung cancer cells expressing mutant p53.
    Nenkov M; Ma Y; Haase D; Zhou Z; Li Y; Petersen I; Lu G; Chen Y
    Oncol Rep; 2020 Jun; 43(6):2073-2082. PubMed ID: 32186773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy Regulated by Gain of Function Mutant p53 Enhances Proteasomal Inhibitor-Mediated Cell Death through Induction of ROS and ERK in Lung Cancer Cells.
    Saini H; Hakeem I; Mukherjee S; Chowdhury S; Chowdhury R
    J Oncol; 2019; 2019():6164807. PubMed ID: 30723502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.
    Vaughan CA; Singh S; Grossman SR; Windle B; Deb SP; Deb S
    Mol Oncol; 2017 Jun; 11(6):696-711. PubMed ID: 28423230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
    Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
    Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
    Barta JA; Pauley K; Kossenkov AV; McMahon SB
    Carcinogenesis; 2020 Mar; 41(1):67-77. PubMed ID: 31067569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NT5DC2 suppression restrains progression towards metastasis of non-small-cell lung cancer through regulation p53 signaling.
    Jin X; Liu X; Zhang Z; Xu L
    Biochem Biophys Res Commun; 2020 Dec; 533(3):354-361. PubMed ID: 32962856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression.
    Lu KH; Li W; Liu XH; Sun M; Zhang ML; Wu WQ; Xie WP; Hou YY
    BMC Cancer; 2013 Oct; 13():461. PubMed ID: 24098911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer.
    Freire Boullosa L; Van Loenhout J; Flieswasser T; De Waele J; Hermans C; Lambrechts H; Cuypers B; Laukens K; Bartholomeus E; Siozopoulou V; De Vos WH; Peeters M; Smits ELJ; Deben C
    Redox Biol; 2021 Jun; 42():101949. PubMed ID: 33812801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
    Zou Y; Ling YH; Sironi J; Schwartz EL; Perez-Soler R; Piperdi B
    J Thorac Oncol; 2013 Jun; 8(6):693-702. PubMed ID: 23575415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
    Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
    Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-324-5p-CUEDC2 Axis Mediates Gain-of-Function Mutant p53-Driven Cancer Stemness.
    Ghatak D; Datta A; Roychowdhury T; Chattopadhyay S; Roychoudhury S
    Mol Cancer Res; 2021 Oct; 19(10):1635-1650. PubMed ID: 34257080
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Deneka AY; Kopp MC; Nikonova AS; Gaponova AV; Kiseleva AA; Hensley HH; Flieder DB; Serebriiskii IG; Golemis EA
    Cancer Res; 2021 Jul; 81(13):3717-3726. PubMed ID: 34006524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
    Cai Y; Yan X; Zhang G; Zhao W; Jiao S
    Oncotarget; 2015 Aug; 6(22):18997-9005. PubMed ID: 25944617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis.
    Jin D; Guo J; Wu Y; Chen W; Du J; Yang L; Wang X; Gong K; Dai J; Miao S; Li X; Su G
    J Exp Clin Cancer Res; 2020 Jan; 39(1):6. PubMed ID: 31906986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The p53 Target Gene SIVA Enables Non-Small Cell Lung Cancer Development.
    Van Nostrand JL; Brisac A; Mello SS; Jacobs SB; Luong R; Attardi LD
    Cancer Discov; 2015 Jun; 5(6):622-35. PubMed ID: 25813352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.